Neurotransmitter disorders

« Back to Disease List

Inclusion Criteria

  • Patient with an abnormal CSF neurotransmitter profile indicating an abnormal HVA, HIAA or pterin profile
  • Patients with symptoms suspicious of dopamine/serotonin deficiency (e.g. movement disorder, gait abnormalities, hypotonia, autonomic features and neurodevelopmental delay)

Exclusion Criteria

  • CSF neurotransmitter highly suggestive of a primary neurotransmitter that would warrant exclusion of this condition e.g. a CSF profile consistent with AADC deficiency would warrant AADC enzyme activity and DDC genetic testing before patient would be eligible
  • Normal CSF neurotransmitter profile
  • No clinical features of a neurotransmitter disorder

Prior genetic testing guidance

  • Results should have been reviewed for all genetic tests undertaken, including disease-relevant genes in exome sequencing data. The patient is not eligible if they have a molecular diagnosis for their condition.
  • Genetic testing should continue according to routine local practice for this phenotype regardless of recruitment to the project; results of these tests must be submitted via the ‘Genetic investigations’ section of the data capture tool to allow comparison of WGS with current standard testing.

PLEASE NOTE: The sensitivity of WGS compared to current diagnostic genetic testing has not yet been established. It is therefore important that tests which are clinically indicated under local standard practice continue to be carried out.

Prior genetic testing genes

Testing of the following genes should be carried out PRIOR TO RECRUITMENT where this is in line with current local practice:

  • As determined by CSF profile

Closing statement 

These requirements will be kept under continual review during the Main Programme and may be subject to change.

« Back to Disease List